**3.1 Linezolid, Sutezolid, Delpazolid and TBI-223**

Linezolid, also known as Zyvox, is a first-generation oxazolidinones which are a class of antibiotics that inhibits bacterial protein synthesis. Linezolid works by binding to a site on the bacterial ribosome thereby preventing the formation of a functional 70S ribosomal unit which is an essential component of the bacterial translation process [14–17]. Linezolid was initially approved for the treatment of infections originating from Gram-positive bacteria and used primarily in the treatment of complicated skin infections such as methicillin-resistant *Staphylococcus aureus* (MRSA). Although linezolid exhibits good antimycobacterial properties, its use is limited to DR-TB as its long term toxicity profile have been associated with neurological disorders resulting from nerve damage as well as immunosuppression resulting from decreased production of vital immune cells required for host defence [16, 17]. Analogues of Linezolid namely Sutezolid, Delpazolid, Posizolid, Contezolid and TBI-223 are second-generation oxazolidinones that are showing promising potential as antimycobacterial agents. This is due to enhanced safety profiles and reduced toxicity compared to Linezolid as well as more potent activity against mycobacteria *in vitro*. Studies and clinical trials for these analogues are ongoing with the hopes that they may also be effective in shortening current TB treatment regimens [16, 18, 19].
